Cargando…
Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway
BACKGROUND: Infection with the hepatitis B virus (HBV) is closely associated with the development of hepatocellular carcinoma (HCC). The osmoregulatory transcription factor nuclear factor of activated T-cells 5 (NFAT5) has been shown to play an important role in the development of many types of huma...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649064/ https://www.ncbi.nlm.nih.gov/pubmed/29052520 http://dx.doi.org/10.1186/s13046-017-0618-x |
_version_ | 1783272493309493248 |
---|---|
author | Qin, Xian Li, Changsheng Guo, Tao Chen, Jing Wang, Hai-Tao Wang, Yi-Tao Xiao, Yu-Sha Li, Jun Liu, Pengpeng Liu, Zhi-Su Liu, Quan-Yan |
author_facet | Qin, Xian Li, Changsheng Guo, Tao Chen, Jing Wang, Hai-Tao Wang, Yi-Tao Xiao, Yu-Sha Li, Jun Liu, Pengpeng Liu, Zhi-Su Liu, Quan-Yan |
author_sort | Qin, Xian |
collection | PubMed |
description | BACKGROUND: Infection with the hepatitis B virus (HBV) is closely associated with the development of hepatocellular carcinoma (HCC). The osmoregulatory transcription factor nuclear factor of activated T-cells 5 (NFAT5) has been shown to play an important role in the development of many types of human cancers. The role of NFAT5 in HBV-associated HCC has never previously been investigated. METHODS: We compared expression profiles of NFAT5, DARS2 and miR-30e-5p in HCC samples, adjacent nontumor tissues and different hepatoma cell lines by quantitative real-time polymerase chain reaction and /or Western blot. Clinical data of HCC patients for up to 80 months were analyzed. The regulatory mechanisms upstream and convergent downstream pathways of NFAT5 in HBV-associated HCC were investigated by ChIP-seq, MSP, luciferase report assay and bioinformation anaylsis. RESULTS: We first found that higher levels of NFAT5 expression predict a good prognosis, suggesting that NFAT5 is a potential tumor-suppressing gene, and verified that NFAT5 promotes hepatoma cell apoptosis and inhibits cell growth in vitro. Second, our results showed that HBV could suppress NFAT5 expression by inducing hypermethylation of the AP1-binding site in the NFAT5 promoter in hepatoma cells. In addition, HBV also inhibited NFAT5 through miR-30e-5p targeted MAP4K4, and miR-30e-5p in turn inhibited HBV replication. Finally, we demonstrated that NFAT5 suppressed DARS2 by directly binding to its promoter. DARS2 was identified as an HCC oncogene that promotes HCC cell cycle progression and inhibits HCC cell apoptosis. CONCLUSION: HBV suppresses NFAT5 through the miR-30e-5p/mitogen-activated protein kinase (MAPK) signaling pathway upstream of NFAT5 and inhibits the NFAT5 to enhance HCC tumorigenesis via the downstream target genes of DARS2. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-017-0618-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5649064 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56490642017-10-26 Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway Qin, Xian Li, Changsheng Guo, Tao Chen, Jing Wang, Hai-Tao Wang, Yi-Tao Xiao, Yu-Sha Li, Jun Liu, Pengpeng Liu, Zhi-Su Liu, Quan-Yan J Exp Clin Cancer Res Research BACKGROUND: Infection with the hepatitis B virus (HBV) is closely associated with the development of hepatocellular carcinoma (HCC). The osmoregulatory transcription factor nuclear factor of activated T-cells 5 (NFAT5) has been shown to play an important role in the development of many types of human cancers. The role of NFAT5 in HBV-associated HCC has never previously been investigated. METHODS: We compared expression profiles of NFAT5, DARS2 and miR-30e-5p in HCC samples, adjacent nontumor tissues and different hepatoma cell lines by quantitative real-time polymerase chain reaction and /or Western blot. Clinical data of HCC patients for up to 80 months were analyzed. The regulatory mechanisms upstream and convergent downstream pathways of NFAT5 in HBV-associated HCC were investigated by ChIP-seq, MSP, luciferase report assay and bioinformation anaylsis. RESULTS: We first found that higher levels of NFAT5 expression predict a good prognosis, suggesting that NFAT5 is a potential tumor-suppressing gene, and verified that NFAT5 promotes hepatoma cell apoptosis and inhibits cell growth in vitro. Second, our results showed that HBV could suppress NFAT5 expression by inducing hypermethylation of the AP1-binding site in the NFAT5 promoter in hepatoma cells. In addition, HBV also inhibited NFAT5 through miR-30e-5p targeted MAP4K4, and miR-30e-5p in turn inhibited HBV replication. Finally, we demonstrated that NFAT5 suppressed DARS2 by directly binding to its promoter. DARS2 was identified as an HCC oncogene that promotes HCC cell cycle progression and inhibits HCC cell apoptosis. CONCLUSION: HBV suppresses NFAT5 through the miR-30e-5p/mitogen-activated protein kinase (MAPK) signaling pathway upstream of NFAT5 and inhibits the NFAT5 to enhance HCC tumorigenesis via the downstream target genes of DARS2. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-017-0618-x) contains supplementary material, which is available to authorized users. BioMed Central 2017-10-19 /pmc/articles/PMC5649064/ /pubmed/29052520 http://dx.doi.org/10.1186/s13046-017-0618-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Qin, Xian Li, Changsheng Guo, Tao Chen, Jing Wang, Hai-Tao Wang, Yi-Tao Xiao, Yu-Sha Li, Jun Liu, Pengpeng Liu, Zhi-Su Liu, Quan-Yan Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway |
title | Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway |
title_full | Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway |
title_fullStr | Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway |
title_full_unstemmed | Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway |
title_short | Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway |
title_sort | upregulation of dars2 by hbv promotes hepatocarcinogenesis through the mir-30e-5p/mapk/nfat5 pathway |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649064/ https://www.ncbi.nlm.nih.gov/pubmed/29052520 http://dx.doi.org/10.1186/s13046-017-0618-x |
work_keys_str_mv | AT qinxian upregulationofdars2byhbvpromoteshepatocarcinogenesisthroughthemir30e5pmapknfat5pathway AT lichangsheng upregulationofdars2byhbvpromoteshepatocarcinogenesisthroughthemir30e5pmapknfat5pathway AT guotao upregulationofdars2byhbvpromoteshepatocarcinogenesisthroughthemir30e5pmapknfat5pathway AT chenjing upregulationofdars2byhbvpromoteshepatocarcinogenesisthroughthemir30e5pmapknfat5pathway AT wanghaitao upregulationofdars2byhbvpromoteshepatocarcinogenesisthroughthemir30e5pmapknfat5pathway AT wangyitao upregulationofdars2byhbvpromoteshepatocarcinogenesisthroughthemir30e5pmapknfat5pathway AT xiaoyusha upregulationofdars2byhbvpromoteshepatocarcinogenesisthroughthemir30e5pmapknfat5pathway AT lijun upregulationofdars2byhbvpromoteshepatocarcinogenesisthroughthemir30e5pmapknfat5pathway AT liupengpeng upregulationofdars2byhbvpromoteshepatocarcinogenesisthroughthemir30e5pmapknfat5pathway AT liuzhisu upregulationofdars2byhbvpromoteshepatocarcinogenesisthroughthemir30e5pmapknfat5pathway AT liuquanyan upregulationofdars2byhbvpromoteshepatocarcinogenesisthroughthemir30e5pmapknfat5pathway |